# Study of the Safety, Tolerability and Efficacy of NP-101 in Treating High Risk Participants Who Are Covid-19 Positive.

> **NCT05785390** · PHASE2 · TERMINATED · sponsor: **Novatek Pharmaceuticals** · enrollment: 170 (actual)

## Conditions studied

- COVID-19

## Interventions

- **DRUG:** NP-101
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT05785390
- **Lead sponsor:** Novatek Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2023-02-22
- **Primary completion:** 2025-05-09
- **Final completion:** 2025-05-09
- **Target enrollment:** 170 (ACTUAL)
- **Why stopped:** The interim analysis results met protocol and SAP predetermined criteria for stopping early due to futility or efficacy.
- **Last updated:** 2025-05-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05785390

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05785390, "Study of the Safety, Tolerability and Efficacy of NP-101 in Treating High Risk Participants Who Are Covid-19 Positive.". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT05785390. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*